Today's market brief features a mix of neutral and positive news from various companies, with some reporting strong financial results and others experiencing stable or declining performance. The overall impact of these announcements is expected to be moderate, with no significant surprises disclosed.
KBC Group reported a strong second quarter with a net profit of 1,152 million euros and raised its 2026 guidance for net interest income and total income, driven by higher net interest income and insurance revenues.
VIEW FILING →Westwing Group Ag reported a 15% year-over-year increase in Gross Merchandise Volume (GMV) and a 14% increase in revenue, but adjusted EBITDA margin was impacted by macro-driven margin pressure and one-off system migration costs.
VIEW FILING →Fortuna Mining Corp reported strong Q2 2026 results with $85.7 million in free cash flow and $200.8 million in adjusted EBITDA, and announced a construction decision for the Séguéla Plant Expansion, which is expected to increase production by 60% to over 500,000 ounces annually.
VIEW FILING →Rational AG reports 8% organic growth and a 6% increase in sales revenues for the first half of 2026, with an EBIT margin of 26.5%.
VIEW FILING →SAF-HOLLAND reported a 1.6% increase in group sales and a significant improvement in cash flow, with adjusted EBIT rising to EUR 85.9 million, but the outlook for fiscal year 2026 remains unchanged.
VIEW FILING →SAF-HOLLAND confirmed its outlook for the full fiscal year 2026, expecting sales between EUR 1,700 million and EUR 1,850 million and an adjusted EBIT margin of 9% to 10%.
VIEW FILING →Carl Zeiss Meditec's revenue is stable on a currency-adjusted basis, but adjusted EBITA margin decreased to 8.0% due to issues in China and softer investment in APAC.
VIEW FILING →Circio's abstract on its circVec platform has been selected for an oral presentation at the prestigious ESGCT annual meeting, highlighting the scientific merit of its proprietary technology, but this is a routine announcement with no quantified surprise.
VIEW FILING →Vivoryon Therapeutics N.V. reported a net loss of EUR 3.4 million for H1 2026 and maintained its financial guidance, with cash expected to fund operations into Q4 2026.
VIEW FILING →The announcement of David Johnson's retirement as Chairman of the Board and Rusty Hutson's assumption of the role is a routine board update with no quantified surprise, and thus unlikely to significantly impact the stock price.
VIEW FILING →The filings and moves that matter, in your inbox every market day.
Subscribe free →